TSPO and glioblastoma: Here, high contralateral TSPO-PET signal was an independent predictor of shorter overall survival within the group of patients with glioblastoma (median OS: 6.5 vs. 13.4 months; HR: 2.18; P = 0.005), together with age (HR: 1.12; P < 0.001), MGMT (HR: 0.20; P = 0.010), glucocorticoid medication (HR: 5.16; P = 0.011), and T1 contrast enhanced volume (HR: 1.04; P = 0.025; Supplementary Table S2).